The images presented in Figure 3 show some heterogeneity in EGFR expression, consistent with the existence of “side populations” in pancreatic cancer cell lines (as described by Yao et al., [43]); in the current publication – which aims to describe a new mechanism for modulating EGFR activity via an MOE approach – this nuance in cell to cell variability is less important than our goal of describing the overall effects of increased flux-based sialylation on the trafficking of EGFR in cells that express this oncogenic protein. The gene discussed is EGFR; the disease is pancreatic neoplasm.